Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients

Clinical Microbiology and Infection

Volumn 19, Issue 6, 2013, Pages

  Lee, J H ^a   Hachiya, A ^b,c   Shin, S K ^a   Lee, J ^a   Gatanaga, H ^c   Oka, S ^c   Kirby, K A ^b   Ong, Y T ^b   Sarafianos, S G ^b   Folk, W R ^b   Yoo, W ^a   Hong, S P ^a   Kim, S O ^a  

^a GeneMatrix Inc   (South Korea)

^b University of Missouri   (United States)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Drug; HIV 1; MALDI TOF; Resistance mutation; RFMP

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ACCURACY; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASSAY; CODON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDRUG RESISTANCE; MUTANT; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; RELIABILITY; RESTRICTION FRAGMENT MASS POLYMORPHISM; SENSITIVITY AND SPECIFICITY; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876782567     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12167     Document Type: Article

References (30)

1. Chen TK, Aldrovandi GM. Review of hiv antiretroviral drug resistance. Pediatr Infect Dis J 2008; 27: 749-752.
2. Boltz VF, Zheng Y, Lockman S et al. Role of low-frequency hiv-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108: 9202-9207.
3. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult hiv infection: 2012 recommendations of the international antiviral society-USA panel. JAMA 2012; 308: 387-402.
4. Hong SP, Shin SK, Lee EH et al. High-resolution human papillomavirus genotyping by maldi-tof mass spectrometry. Nat Protoc 2008; 3: 1476-1484.
5. Oh HB, Kim SO, Cha CH et al. Identification of hepatitis c virus genotype 6 in korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism. J Med Virol 2008; 80: 1712-1719.
6. Cha CK, Kwon HC, Cheong JY et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis b. J Med Virol 2009; 81: 417-424.
7. Cha YS, Choi SH, Lee JH et al. Analysis of tpox short tandem repeat locus with matrix-associated laser desorption/ionization time-of-flight-based restriction fragment mass polymorphism assay. Anal Biochem 2011; 412: 79-84.
8. Cho SW, Koh KH, Cheong JY et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis b patients with prior lamivudine resistance. J Viral Hepatitis 2010; 17: 171-177.
9. Choe WH, Hong SP, Kim BK et al. Evolution of hepatitis b virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009; 14: 985-993.
10. Han KH, Hong SP, Choi SH et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis b. Antivir Ther 2011; 16: 77-87.
11. Kim SS, Cheong JY, Lee D et al. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis b. J Med Virol 2012; 84: 18-25.
12. Lee JM, Kim HJ, Park JY et al. Rescue monotherapy in lamivudine-resistant hepatitis b e antigen-positive chronic hepatitis b: Adefovir versus entecavir. Antivir Ther 2009; 14: 705-712.
13. Kodama EI, Kohgo S, Kitano K et al. 4'-ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45: 1539-1546.
14. Kim HS, Han KH, Ahn SH et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis b patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-449.
15. Tsibris AM, Hirsch MS. Antiretroviral therapy in the clinic. J Virol 2010; 84: 5458-5464.
16. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. Structural aspects of drug resistance and inhibition of hiv-1 reverse transcriptase. Viruses 2010; 2: 606-638.
17. Sarafianos SG, Marchand B, Das K et al. Structure and function of hiv-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009; 385: 693-713.
18. Tang MW, Shafer RW. Hiv-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72: e1-e25.
19. Underwood MR, Ross LL, Irlbeck DM et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by k65r or m184v in mixtures with wild-type hiv-1. J Infect Dis 2009; 199: 84-88.
20. Qari SH, Winters M, Vandamme AM, Merigan T, Heneine W. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant hiv-1 in plasma. Antivir Ther 2002; 7: 131-139.
21. Sen S, Tripathy SP, Paranjape RS. Antiretroviral drug resistance testing. J Postgrad Med 2006; 52: 187-193.
22. Garcia-Gonzalez C, Garcia-Bujalance S, Ruiz-Carrascoso G et al. Detection and quantification of the k103n mutation in hiv reverse transcriptase by pyrosequencing. Diagn Microbiol Infect Dis 2012; 72: 90-96.
23. Clevenbergh P, Durant J, Halfon P et al. Persisting long-term benefit of genotype-guided treatment for hiv-infected patients failing haart. The viradapt study: week 48 follow-up. Antivir Ther 2000; 5: 65-70.
24. Cortez KJ, Maldarelli F. Clinical management of hiv drug resistance. Viruses 2011; 3: 347-378.
25. Erali M, Page S, Reimer LG, Hillyard DR. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol 2001; 39: 2157-2165.
26. Garcia-Bujalance S, de Guevara CL, Gonzalez-Garcia J, Arribas JR, Gutierrez A. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. J Clin Microbiol 2005; 43: 4186-4188.
27. Rothberg JM, Leamon JH. The development and impact of 454 sequencing. Nat Biotechnol 2008; 26: 1117-1124.
28. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437: 376-380.
29. Hert DG, Fredlake CP, Barron AE. Advantages and limitations of next-generation sequencing technologies: a comparison of electrophoresis and non-electrophoresis methods. Electrophoresis 2008; 29: 4618-4626.
30. Nagy E, Maier T, Urban E, Terhes G, Kostrzewa M. Species identification of clinical isolates of bacteroides by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2009; 15: 796-802.